利索-全球专利检索

  1. 登录
  2. 注册
发明公开
EP3160505A1 ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS 审中-公开
抗体-PD-L1抗原克隆抗体在维他命C

  • 专利标题： ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
  • 专利标题（中）： 抗体-PD-L1抗原克隆抗体在维他命C
  • 申请号： EP15815646.3
    申请日： 2015-07-01
  • 公开(公告)号： EP3160505A1
    公开(公告)日： 2017-05-03
  • 发明人: LI, Kang , SONG, Jing , ZHANG, Tong , LI, Yucheng , REN, Zhiying , KANG, Yanshen
  • 申请人： BeiGene, Ltd.
  • 申请人地址： Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY
  • 专利权人： BeiGene, Ltd.
  • 当前专利权人： BeiGene, Ltd.
  • 当前专利权人地址： Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY
  • 代理机构： Regimbeau
  • 优先权： PCT/CN2014/081581 20140703
  • 国际公布： WO2016000619 20160107
  • 主分类号： A61K39/395
  • IPC分类号： A61K39/395 ;  C07K16/46 ;  G01N33/574 ;  A61K39/00 ;  C07K16/28
ANTI-PD-L1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS
摘要：
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
摘要（中）：

提供了特异性结合程序性死亡-1（PD1，Pdcd-1或CD279）配体（PD-L1）并抑制PD-L1介导的免疫细胞中的细胞信号和活性的抗体，与一组氨基酸结合的抗体 其配体结合所需的残基，以及这些抗体用于治疗或诊断由PD-L1介导的功能调节的癌症，感染性疾病或其他病理学障碍的用途。

信息查询
Global Dossier Espacenet
0/0